Newsroom
Strive to Deliver Breakthroughs
-
June 05, 2018
Harbour BioMed and The Wistar Institute Join Forces to Advance Novel Antibody Therapies for Cancer and Infectious Diseases
Collaboration combines Harbour’s proprietary H2L2 transgenic mouse platform for generating fully human monoclonal antibodies with Wistar’s cancer b...
View more -
June 05, 2018
Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with Celsius Therapeutics for Fully Human Monoclonal Antibody Drug Discovery
SHANGHAI & ROTTERDAM, NETHERLANDS & CAMBRIDGE, MA - May 31, 2018 - Harbour BioMed announced today that it has licensed its patented H2L2 fully hum...
View more -
April 24, 2018
Harbour BioMed will give a presentation at PEGS-Boston Conference 2018
April 30th – May 4th, 2018 Seaport World Trade Center Boston, MA Please stop by our Booth 601! Oncology Stream Lu...
View more -
January 23, 2018
Harbour BioMed Completes Series A+ Round Financing to Accelerate the Development of Clinical Programs and Company Growth
January 22, 2018 SHANGHAI, China, ROTTERDAM, The Netherlands and CAMBRIDGE, MA Harbour BioMed announced today that it has completed a Seri...
View more -
January 08, 2018
Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with BeiGene for Fully Human Monoclonal Antibody Drug Discovery
January 7, 2018 SHANGHAI, China, ROTTERDAM, The Netherlands and CAMBRIDGE, MA Harbour BioMed announced today that it has licensed its pate...
View more -
January 08, 2018
Harbour BioMed Enters Agreement to Develop Fully Human Antibody Fragments for Innovative CAR-T Therapy
January 8th, 2018 SHANGHAI, China, ROTTERDAM, The Netherlands and CAMBRIDGE, MA Harbour BioMed announced today that it has entered into an...
View more -
December 05, 2017
Harbour Biomed will give a presentation at Antibody Engineering and Therapeutics Conference 2017 in San Diego
Dec. 11th- 15th, 2017 Manchester Grand Hyatt San Diego, San Diego, CA Please stop by our Booth 121! Scientific Breakfast Briefing...
View more -
October 12, 2017
Harbour BioMed Announces Multi-Year Transgenic Platform Licensing Agreement with Innovent Biologics, Inc. for Fully Human Monoclonal Antibody Drug Discovery
October 12th, 2017 SHANGHAI, China, ROTTERDAM, The Netherlands and CAMBRIDGE, MA Harbour BioMed announced today that it has lice...
View more -
December 19, 2016
Harbour BioMed Acquires Harbour Antibodies to Create Global, Oncology-focused Biotechnology Company
Transgenic Mouse Platform Technology Licensing to Continue, Expand to Include Collaborative Discovery/Development Partnerships Cambridge, MA, Shangh...
View more
Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号
沪ICP备19015946号-1